A clinical trial out of Memorial Sloan Kettering Cancer Center has set the cancer community abuzz after it showed a 100 percent success rate among the first 14 participants who completed treatment.
Whether Dr. Hitchins’ research will ultimately produce a new screening test remains to be seen, but the progress made toward that end has relied greatly on the Alliance’s support.
Non-Hispanic Black men have the worst colorectal cancer survival rates of any demographic group, and they are less likely than their non-Hispanic White counterparts to get screened.
This new technology could refine the prognosis of stage II and some low-risk stage III colon cancer patients and provide doctors with additional information when making decisions about chemotherapy treatment.
If there is one common theme in all of the literature and scientific papers, it is that cannabis and cannabinoids enhance the benefits of conventional treatment for side effect management.
Our nation’s investment in cancer research and prevention is saving lives. Cancer mortality rates have declined by 33% since 1990, and the Biden administration’s Cancer Moonshot has a goal of 50%.
Developing a Lynch Syndrome vaccine could change the narrative for patients, reducing screenings and – more importantly – lowering risks for Lynch Syndrome-related cancers.
Lynch Syndrome is the most common cause of hereditary colorectal cancer, resulting in 4,200 cases per year. It is also more common in younger adults than in other forms of colorectal cancer.
Driven by a commitment to save lives through best practices and innovation in research participation, the group offered collaborative solutions to improve trial design, messaging, access, and navigation, and ultimately, increase participation.
Results of a new study announced at the 2023 ASCO Gastrointestinal Cancers Symposium demonstrate that a combination therapy, trifluridine/tipiracil (Lonsurf) plus bevacizumab, has promising activity to increase lifespan in mCRC patients.
Evan Daniels is no stranger to the presence of cancer in his life. His father, Robert Daniels, was diagnosed with stage II colon cancer when Evan was just eight years old. Fortunately, Robert’s disease was caught early, and he was able to watch Evan grow.
The Colorectal Cancer Alliance is committed in 2024 to finally getting Congress to include colorectal cancer as a dedicated research program at the CDMRP.
A veteran in the field of gastrointestinal cancer research, Dr. Marshall will share his leadership experience and scientific expertise to guide the Alliance’s patient support and research initiatives, particularly Project Cure CRC.
The Colorectal Cancer Alliance’s philanthropic research fund, Project Cure CRC, has announced another awardee. Peter P. Lee, MD, of City of Hope will receive $1 million over two years.
The Colorectal Cancer Alliance’s philanthropic research fund, Project Cure CRC, has announced another awardee. Kevin Van Der Jeught, Ph.D., of the University of Miami, will receive $200,000 over two years.
The Colorectal Cancer Alliance’s philanthropic research fund, Project Cure CRC, has announced another awardee. Yekaterina Zaytseva, PhD, of the University of Kentucky will receive $200,000 over two years.